A highly-regarded industry leader and founding partner of Green, Griffith & Borg-Breen, Bob’s influence extends from the courtroom to corporate board rooms to the shelves of neighborhood drugstores. His work as lead counsel for both plaintiffs and defendants since the 1984 passage of the Hatch-Waxman Act has affected more than 40 drug products.
Bob’s aim has always been to provide clients with personalized IP advice and guidance tailored precisely to their business needs. Clients rely on his vast firsthand understanding of the complex issues they face; they value his strategic counsel to weigh their legal options against business goals and considerations and they trust him to work tirelessly to accomplish those goals.
Adept at formulating winning patent strategies for both brand and generic pharmaceutical companies, Bob also assists clients in navigating issues related to the interplay between the FDA and the pharma industry. Bob has broad experience in managing patent portfolios as well as in counseling and rendering opinions on patent validity, patent infringement and other proprietary information across multiple industries. Bob has argued numerous pharmaceutical patent appeals before the U.S. Court of Appeals for the Federal Circuit.
When co-founding Green Griffith, Bob and his partners sought out attorneys who, like themselves, offered deep scientific knowledge coupled with a passion for client-centered legal strategy.
“We’re not Big Law, and we don’t want to be Big Law,” Bob says. “We’re all about depth. As a team, we’ve been working in this space for as long as anyone could be. The focus, experience and perspective our team brings to each matter is second to none.”
Prior to founding Green Griffith in 2015, Bob served as vice president of Leydig, Voit & Mayer, Ltd. He previously worked as lead patent counsel for Akzo’s chemical division and as the Patent Counsel for Celanese Chemical.